Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29528946 | 1.00 | MDM4 (0.50) | MDM4TP53GPR34MDM2CASP3 | |
| SCHEMBL29907902 | 1.00 | MDM4 (0.50) | MDM4TP53GPR34MDM2CASP3 | |
| SCHEMBL119454 | 1.00 | MDM4 (0.50) | MDM4TP53GPR34MDM2CASP3 | |
| SCHEMBL30686154 | 1.00 | MDM4 (0.50) | MDM4TP53GPR34MDM2CASP3 | |
| SCHEMBL3727547 | 1.00 | MDM4 (0.50) | MDM4TP53GPR34MDM2CASP3 | |
| SCHEMBL31369461 | 0.95 | MDM4 (0.50) | MDM4TP53GPR34MDM2CASP3 | |
| SCHEMBL30813308 | 0.91 | MDM4 (0.49) | MDM4TP53MDM2CASP3EPHX2 | |
| SCHEMBL27172943 | 0.91 | MDM4 (0.49) | MDM4TP53MDM2CASP3EPHX2 | |
| SCHEMBL30813350 | 0.91 | MDM4 (0.49) | MDM4TP53MDM2CASP3EPHX2 | |
| SCHEMBL27205008 | 0.91 | MDM4 (0.49) | MDM4TP53MDM2CASP3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| WO-2022234853-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | FUJIFILM CORPORATION (JP) | 2022-05-03 | — | — | US | disclosed |
| US-20200040039-A1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM CORPORATION (JP) | 2020-02-06 | — | — | US | disclosed |
| EP-3604326-A1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM Corporation (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20110230419-A1 | IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| EP-2318363-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | Nuevolution A/S (DK) | 2011-05-11 | — | — | EP | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885GPR34 2449/4885 |
| US-20200040039-A1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | VIP, NPPA, NGLY1 | MDM4 4154/4885TP53 1409/4885GPR34 1284/4885 |
| US-20110230419-A1 | IAP BINDING COMPOUNDS | BIRC5, BIRC7, BIRC3 | MDM4 219/4885TP53 17/4885GPR34 2632/4885 |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | VIP, NPPA, NGLY1 | MDM4 4154/4885TP53 1409/4885GPR34 1284/4885 |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | MDM4 1060/4885TP53 573/4885GPR34 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.